Cargando…
RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study
BACKGROUND: The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown. We determined the level...
Autores principales: | Xu, Ruomei, Fathima, Parveen, Strunk, Tobias, de Klerk, Nicholas, Snelling, Thomas L., Richmond, Peter C., Keil, Anthony D., Moore, Hannah C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584096/ https://www.ncbi.nlm.nih.gov/pubmed/33092566 http://dx.doi.org/10.1186/s12887-020-02390-5 |
Ejemplares similares
-
Using record linkage to demonstrate the benefits of maternal influenza immunisation in Western Australia
por: Regan, Annette, et al.
Publicado: (2017) -
Record linkage study of the pathogen‐specific burden of respiratory viruses in children
por: Lim, Faye J., et al.
Publicado: (2017) -
Association between pertussis vaccination in infancy and childhood asthma: A population-based record linkage cohort study
por: Pérez Chacón, Gladymar, et al.
Publicado: (2023) -
Impact of Rotavirus Vaccines on Gastroenteritis Hospitalizations in Western Australia: A Time-series Analysis
por: Fathima, Parveen, et al.
Publicado: (2021) -
Impact of the Four-Hour Rule in Western Australian hospitals: Trend analysis of a large record linkage study 2002-2013
por: Ngo, Hanh, et al.
Publicado: (2018)